Sunday, 1 November 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

INTEXA Stock Bearish Momentum With A 16% Fall In The Last 5 Sessions

Loading stream...

(vianews) - shares of intexa (cac 40: itxt.pa) slid by a staggering 16.44% in 5 sessions from €2.92 to €2.44 at 19:54 est on thursday, after four sequential sessions in a row of losses. cac 40 is jumping 2.03% to €7,025.72, following the last session's downward trend.

about intexa

intexa s.a. engages in the operation of the photovoltaic installation in saint-andré-de-cubzac, france. the company was founded in 2011 and is headquartered in saint-etienne, france. intexa s.a. is a subsidiary of casino guichard-perrachon.

earnings per share

as for profitability, intexa has a trailing twelve months eps of €0.1.

pe ratio

intexa has a trailing twelve months price to earnings ratio of 24.4. meaning, the purchaser of the share is investing €24.4 for every euro of annual earnings.

more news about intexa (itxt.pa).

Categories

stockMarket

Tags

INTEXAStock PriceITXT.PAPrice DownMarket Session NowStock Price DownStock Market NowMarket SessionStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com